Healius Limited (ASX: HLS)

Healius Limited is a healthcare company. The Company’s segments include Pathology and Imaging. The Pathology segment is a provider of pathology services, including specialty pathology and clinical trials. The Imaging segment provides imaging services from standalone imaging sites, hospitals and medical centers.

It has a network of pathology laboratories, collection centers and diagnostic imaging centers. It provides specialty diagnostic services to consumers and their referring practitioners. Its brands include Laverty Pathology, QML Pathology, Dorevitch Pathology, Western Diagnostic Pathology, Genomic Diagnostics, Abbott Pathology, IQ Pathology, Vetnostics, TML Vetnostics, Agilex Biolabs, Lumus Imaging, and others.

Its Pathology operates 100 medical laboratories and 2,000 patient collection centers across metropolitan, regional and remote Australia. IQ Pathology is a specialized dermatopathology laboratory that provides comprehensive dermatopathology services Australia wide.

Top Australian Brokers

City Index - Aussie shares from $5 - Read our review
Pepperstone - Trading education - Read our review
IC Markets - Experienced and highly regulated - Read our review
eToro - Social and copy trading platform - Read our review

REVENUE IN AUD (TTM)

1.69bn

NET INCOME IN AUD

-984.10m

Year on year Healius Ltd’s revenues fell -25.43% from 2.29bn to 1.71bn. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a gain of 307.90m to a loss of 367.80m.